• Journal of Ginseng Research
• /
• 제41권4호
• /
• pp.450-455
• /
• 2017

Chronic liver disease, one of the most common diseases, typically arises from nonalcoholic fatty liver disease, alcoholic liver disease, chronic viral hepatitis, or hepatocellular carcinoma. Therefore, there is a pressing need for improved treatment strategies. Korean Red Ginseng has been known to have positive effects on liver disease and liver function. In this paper, we summarize the current knowledge on the beneficial effects of Korean Red Ginseng on chronic liver disease, a condition encompassing nonalcoholic fatty liver disease, alcoholic liver disease, chronic viral hepatitis, and hepatocellular carcinoma, as supported by experimental evaluation and clinical investigation.

• 대한의생명과학회지
• /
• 제9권4호
• /
• pp.209-214
• /
• 2003

To determine the clinical usefulness of Immuno Blot test, 160 samples from the patients with chronic HCV infection were analyzed. And serotyping and line probe assay were performed to evaluate the distribution of hepatitis C virus genotypes in Korean isolates. In this group, as a result of genotyping type 1 band 2a, the serotype I and II were the most common source of HCV infection. There were no significant difference in response to the alpha-interferon HCV infection treatment with the subtype 1 b or 2a. And the serotypes of NS4 peptides were compared with the genotypes to evaluate their clinical usefulness. Among 49 cases studied for genotypes and serotype, genotype 1 b, 1 b/2b, 2a, 2a/2c and 2b were 51.0％, 2.0％, 34.6％, 8.1％ and 4.0％, respectively. The serotypes I and II were 57.1％ and 42.8％, respectively; they were matched with genotypes in 85.7％ and seemed to be easy to perform. To monitor their performing progress or treatment response, serotype test was made before the genotype test. The Result showed that there was no significant difference in response to the alpha-interferon HCV infection treatment with the subtype 1 b or 2a in Korea.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제12권1호
• /
• pp.88-92
• /
• 2009

산발성 C형 간염 환자의 약 40%에서 감염경로가 확실치 않다. 이러한 환자들에서 HCV 감염이 수혈, 투석, 수술, 수직감염 및 성적 접촉 등의 잘 알려진 감염 경로 이외에도 침, 귓불 천공 등의 경피적 경로를 통해 전파 될 수 있음을 간과하지 말아야 할 것이다. 저자들은 간염의 가족력이나 수술과 수혈 과거력이 없는 10세 여아에서 피어싱과 침술로 인해 발생한 만성 C형 간염을 진단하고, pegylated interferon과 경구 ribavirin으로 치료한 증례를 경험하였기에 문헌고찰과 함께 보고 한다.

• Molecules and Cells
• /
• 제45권10호
• /
• pp.702-717
• /
• 2022

Hepatitis C virus (HCV) infection can lead to chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. HCV employs diverse strategies to evade host antiviral innate immune responses to mediate a persistent infection. In the present study, we show that nonstructural protein 5A (NS5A) interacts with an NF-κB inhibitor immunomodulatory kinase, IKKε, and subsequently downregulates beta interferon (IFN-β) promoter activity. We further demonstrate that NS5A inhibits DDX3-mediated IKKε and interferon regulatory factor 3 (IRF3) phosphorylation. We also note that hyperphosphorylation of NS5A mediates protein interplay between NS5A and IKKε, thereby contributing to NS5A mediated modulation of IFN-β signaling. Lastly, NS5A inhibits IKKε-dependent p65 phosphorylation and NF-κB activation. Based on these findings, we propose NS5A as a novel regulator of IFN signaling events, specifically by inhibiting IKKε downstream signaling cascades through its interaction with IKKε. Taken together, these data suggest an additional mechanistic means by which HCV modulates host antiviral innate immune responses to promote persistent viral infection.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권13호
• /
• pp.5515-5519
• /
• 2015

The single nucleotide polymorphism (SNP) ss469415590 in the interferon lambda-4 (IFNL4) gene has recently been reported to have an association with treatment response in chronic hepatitis C. However, any importance of the SNP in association with response to pegylated interferon (PEG-IFN) therapy in patients with chronic hepatitis B (CHB) is unclear. We retrospectively analyzed data for Thai patients with CHB treated with PEG-IFN for 48 weeks. Virological response (VR) for HBeAg-positive CHB was defined as HBeAg seroconversion plus HBV DNA level <2,000 IU/mL at 24 weeks post-treatment. VR for HBeAg-negative CHB was defined as an HBV DNA level <2,000 IU/mL at 48 weeks. The SNP was identified by real time PCR using the TaqMan genotyping assay with MGB probes. A total 254 patients (107 HBeAg-positive and 147 HBeAg-negative) were enrolled in the study. The distribution of TT/TT, ${\Delta}G/TT$ and ${\Delta}G/{\Delta}G$ genotypes was 221 (87.0%), 32 (12.6%) and 1 (0.4%), respectively. Patients with non-TT/TT genotypes had significantly higher baseline HBV DNA levels than patients with the TT/TT genotype. In HBeAg-positive CHB, 41.2% of patients with TT/TT genotype versus 50.0% with non-TT/TT genotype achieved VR (P=0.593). In HBeAg-negative CHB, the corresponding figures were 40.3% and 43.5%, respectively (P=0.777). There was no significant correlation between the SNP genotypes and HBsAg clearance in both groups of patients. In summary, ss469415590 genotypes were not associated with response to PEG-IFN in Thai patients with HBeAg-positive and HBeAg-negative CHB.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제8권2호
• /
• pp.202-212
• /
• 2005

목 적: Transfusion-transmitted virus는 간염과의 연관성이 아직 명확하지 않지만 특정 유전형이 원인불명의 간염 병원체로 작용하거나 다른 간염 바이러스와 중복 감염되어 임상 경과에 영향을 줄 가능성에 대한 연구가 필요하다. 본 연구는 국내 소아 B형 간염, C형 간염 및 원인 불명의 간염 환자의 TTV DNA 양성률과 유전형의 분포를 알아보기 위해 시행하였다. 방 법: 간 기능이 정상인 소아 88명을 대조군으로 하였으며 B형 간염 환자 14명, C형 간염 환아 12명, 2001년 6월부터 2004년 6월까지 인제의대 상계백병원을 방문한 원인 불명의 간염 환자 25명을 대상으로 하였다. 환아의 혈청 검체를 대상으로 N22 시발체를 이용한 PCR과 5'NCR 시발체를 이용한 PCR을 시행하였다. 또한 TLMV DNA 검출을 위한 seminested PCR을 시행 하였다. N22 primer를 이용한 PCR 양성 산물을 대상으로 염기서열의 직접 분석이 시행되었다. 결 과: 1) N22 시발체를 이용한 TTV DNA 양성률은 대조군에서 11.3%, 간염군에서 19.6%였다(p=0.105). B형 간염의 28.5%, C형 간염의 25%, 원인 불명의 간염 24%에서 TTV DNA가 양성이었으며 대조군에 비해 유의한 차이는 없었다. 2) 5'NCR 부위 시발체를 이용한 TTV DNA 양성률은 대조군에서 32.9%, 간염군에서 54.9%였다. B형 간염의 71.4%, C형 간염의 50%, 원인 불명의 간염 48%에서 TTV DNA가 양성이었다. B형 간염 환자군에서 양성률이 대조군에 비해 높았다(p=0.008). 3) 5'NCR 부위 시발체를 이용한 TLMV DNA양성률은 간염 환자군과 정상 대조군에서 각각 29.4% (15/51명), 48.9% (43/88명)였다. B형 간염 21.4% (3/14), C형 간염 16.6% (2/12), 원인 불명의 간염 환자에서 40% (10/25)였다. 4) 염기 서열 분석: N22 시발체를 이용해서 PCR 반응 산물 중 총 29예(간염 환자 8명, 대조군 11명)의 염기서열을 분석한 결과 G1 유전형은 10예(52%)였고 이 중 G1a형이 7예였다. G2 유전형은 3예, G3 유전형은 2예였으며 나머지는 정확한 분류가 되지 않았다. 결 론: 국내 소아에 감염된 TTV 유전형 중 가장 흔한 것은 G1형이었다. TTV DNA 양성률은 대조군과 원인 불명의 간염군 간에 차이는 없었으며, B형 간염군에서 대조군에 비해 높았다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권17호
• /
• pp.7213-7218
• /
• 2014

Background: Egypt has one of the highest prevalences of hepatitis C virus (HCV) infection worldwide. Although the IL28B gene polymorphism has been shown to modify the course of chronic HCV infection, this has not been properly assessed in the Egyptian population. Materials and Methods: The IL28B rs12979860 single nucleotide polymorphism (SNP) was therefore examined in 256 HCV-infected Egyptian patients (group II) at different stages of disease progression and in 48 healthy volunteers (group I). Group II was subdivided into GII-A (chronic hepatitis patients, n=119), GII-B (post hepatitis cirrhosis, n=66) and GII-C (HCC on top of cirrhosis, n=71). Results: The C/T genotype was the commonest in all groups. It was more frequent in GI (52%) than in GII (48%). There was no significant difference in the frequency of C/T and C/C or T/T genotypes between groups and subgroups (p=0.82). Within the subgroups; the C/C genotype was more common in GII-B while C/T and T/T genotypes were more common in GII-C, though with no significant difference (p=0.59 and p=0.80). There was no significant association between IL28B rs12979860 SNP and viral load, ALT, AFP level, METAVIR scores for necro-inflammation and fibrosis, and Child-Pugh classification. Conclusions: 1) IL28Brs12979860 C/T genotype is the commonest genotype in HCV-associated CH and HCC in Egypt. 2) IL28Brs12979860 polymorphisms are not associated with disease progression or aggression (histological staging, severity of fibrosis in CH or the incidence of post-HCV HCC). 3) Differences in IL28Brs12979860 genotypes could be a consequence of environmental or ethnic variation.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제9권2호
• /
• pp.242-248
• /
• 2006

목 적: 비-가족형, 비-대사성, 비-A, B, C형 바이러스성 신생아 간염은 양호한 경과를 취한다고 알려져 있지만, 장기적인 경과 관찰에 대한 연구가 부족하다. 연자들은 이 질환의 임상적 특징을 연구하여 임상 경과 및 예후 예측에 도움을 얻고자 하였다. 방 법: 1998년 1월부터 2004년 1월까지 생후 3개월 이내에 부산대학교병원에서 신생아 간염으로 진단되었던 환자 중 임상 소견 및 생화학적 검사의 이상 소견이 6개월 이상 지속되었던 34명을 대상(A, B, C형 바이러스성, 대사성, 유전성 신생아 간염은 제외)으로 하여 임상적 소견, 검사실 소견 및 조직학적 소견을 병력지와 조직 슬라이드 분석을 통해 후향적으로 연구를 시행하였다. 결 과: 성비는 2.4 : 1로 남아가 많았고, 진단 시 연령은 생후 1~2개월 사이가 가장 많았다. 혈청 ALT의 최고치의 범위는 광범위(100~1,000 IU/L)하였으나, 300 IU/L 미만이 41%였다. 혈청 직접형 빌리루빈의 최고치는 50%에서 1.0~5.0 mg/dL 사이였다. CMV에 대한 IgM 항체 검사 또는 PCR 검사에서 34%가 양성이었다. 추적 기간의 조건을 충족한 29명 중 11명(37.9%)의 환자가 1년 이내에 ALT 수치가 정상화되었고, 1년 이상 ALT 수치가 증가된 환자 13명 중에서는 2년 이내에 정상화된 경우가 9명(69.2%), 2년 이상 지속적으로 상승된 경우가 4명(30.7%)였다. 2년 이상 지속적으로 ALT 수치의 상승이 있었던 경우 간 조직 검사에서 간문맥 주변 섬유화, 간문맥 염증 및 간소엽 염증 등의 변화가 2년 이내에 회복된 경우보다 심했으나 통계학적인 의미는 없었다. 결 론: 비-가족형, 비-대사성, 비-A, B, C형 바이러스성 신생아 간염은 비교적 예후가 양호하지만 혈청 ALT 수치의 상승이 1년 이상 지속 시 간 손상의 정도에 대한 평가와 만성 간질환에 대한 주의 깊은 관찰이 필요하다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권8호
• /
• pp.3253-3256
• /
• 2015

Background: Chronic hepatitis B virus (HBV) infection related hepatocellular carcinoma (HCC) is a major health problem in the Asia-Pacific region including Thailand. Several factors have been proposed as contributing to hepatocarcinogenesis. This study was aimed to investigate the impact of CYP2C19 genotypic polymorphism in HCC related to chronic HBV infection in Thailand. Materials and Methods: A cross-sectional study was performed between April 2014 and January 2015. Chronic HBV patients with HCC (n=50) and without HCC (n=50) were included. Clinical information and blood samples of all patients were collected. The CYP2C19 genotype was determined by polymerase chain reaction-restriction fragment length polymorphism method, and was classified as rapid metabolizer (RM), intermediate metabolizer (IM) or poor metabolizer (PM). Results: The CYP2C19 genotype frequencies of RM, IM and PM in HBV patients were found to be 19/50 (38%), 25/50 (50%) and 6/50 (12%), respectively. The CYP2C19 genotype frequencies of RM, IM and PM in HBV with HCC patients were 21/50 (42%), 25/50 (50%) and 4/50 (8%), respectively. The distribution of CYP2C19 genotype was not different between patients with and without HCC. Interestingly, among HBV with HCC patients, the RM genotype of CYP2C19 tended to increase risk of aggressive manifestation (OR=2.89, 95%CI=0.76-11.25, P-value=0.07), compared with non RM genotype carriers. Conclusions: CYP2C19 genotype IM was the most common genotype in Thai patients with chronic HBV infection. In addition, genotype RM could be an associated factor for aggressive presentation in HCC related to chronic HBV infection.

• Molecules and Cells
• /
• 제40권6호
• /
• pp.418-425
• /
• 2017

Interferon-${\gamma}$-inducible protein 10 (IP-10), also known as chemokine C-X-C motif ligand (CXCL) 10, is closely associated with antiviral immunity and the progression of chronic hepatitis B (CHB). However, the value of baseline serological and histological IP-10 expression levels in predicting the efficacy of the antiviral response to nucleoside/nucleotide analogues (NAs) is still unknown. In our research, intrahepatic and peripheral IP-10 expression levels were systemically examined before and after treatment with entecavir (ETV). Baseline serological and histological IP-10 expression levels were significantly increased in patients with CHB, particularly in patients with higher degrees of liver inflammation and liver fibrosis. Moreover, higher baseline intrahepatic IP-10 levels indicated better prognoses in patients with CHB after entecavir therapy. The baseline IP-10 level was also positively associated with several clinical parameters, including baseline levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), hepatitis B virus (HBV) DNA, and hepatitis B surface antigen (HBsAg), and with the decrease in HBsAg levels after treatment. In addition, monocyte-derived IP-10 was expressed at higher levels in patients with CHB than in patients with liver cirrhosis (LC) and healthy controls (HC). According to the results of our in vitro experiments, IP-10 directly promoted hepatocyte apoptosis. Based on these findings, baseline serological and histological IP-10 levels might predict CHB severity and the decrease in HBsAg levels after entecavir therapy.